One phase II study by Xiong et al. using cetuximab plus gemcitabine to treat EGFR-expressing advanced pancreatic cancer showed promising results with 63% of the 41 patients enrolled achieving stable disease, although subsequent studies have failed to replicate this [62,63,64,65]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.